Fig. 3
MMN patient-derived IgM binding to SCs is GM2 specific. Sera from MMN patients with IgM anti-GM2 were selected, incubated with soluble GM1 or GM2 and tested for IgM binding to SCs and in the anti-GM2 ELISA. (A) FCIgM binding on SCs before (grey bars) and after (orange bars) pre-incubation with GM1. (B) FCIgM binding on SCs before (grey bars) and after (blue bars) pre-incubation with GM2. (C) Quantification of flow cytometric results depicted in (A and B) as % inhibition. IgM binding is significantly decreased upon pre-incubation with GM2, whereas pre-incubation with GM1 only does not significantly decrease IgM binding. (D) Anti-GM2 specific ELISA showing IgM binding (in d-OD450nm) without (grey bar) or with pre-incubation with GM1 (orange bars) or GM2 (blue bars) using IgM anti-GM2 positive MMN patient sera. (E) Quantification of ELISA results depicted in (D) as % inhibition. Pre-incubation with GM2 significantly lowers IgM binding. Mean + SD, Kruskal-Wallis, post-hoc Dunn’s multiple comparisons test. **** p < 0.0001; ns: non-significant